Tofacitinib

Drug Profile

Tofacitinib

Alternative Names: Cp-690-550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Xeljanz; Xeljanz XR

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Johns Hopkins University; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Nitriles; Piperidines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase III Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Phase II Atopic dermatitis
  • Phase I Dermatomyositis
  • Discontinued Ankylosing spondylitis; Asthma; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection

Most Recent Events

  • 15 Mar 2017 Registered for Rheumatoid arthritis (In adults, Treatment experienced) in China (PO)
  • 14 Mar 2017 Preregistration for Rheumatoid arthritis (In adults, Treatment experienced) in China (PO) before March 14, 2017
  • 20 Feb 2017 Efficacy and adverse events data from pooled analysis of two phase III trials in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top